FMP

FMP

Enter

DBTX - Decibel Therapeutics...

Financial Summary of Decibel Therapeutics, Inc.(DBTX), Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and devel

photo-url-https://financialmodelingprep.com/image-stock/DBTX.png

Decibel Therapeutics, Inc.

DBTX

NASDAQ

Inactive Equity

Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.

4.91 USD

-0.04 (-0.815%)

About

ceo

Dr. Laurence E. Reid Ph.D.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. T...

CIK

0001656536

ISIN

US24343R1068

CUSIP

24343R106

Address

1325 Boylston Street

Phone

617 370 8701

Country

US

Employee

68

IPO Date

Feb 12, 2021

Summary

CIK

0001656536

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

24343R106

ISIN

US24343R1068

Country

US

Price

4.91

Beta

-0.4

Volume Avg.

214.74k

Market Cap

123.37M

Shares

-

52-Week

1.61-5.4

DCF

0

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-1.93

P/B

-

Website

https://www.decibeltx.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest DBTX News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep